111 Capital Cuts Stock Holdings in Bristol Myers Squibb Company $BMY

111 Capital reduced its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 80.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 3,820 shares of the biopharmaceutical company’s stock after selling 16,218 shares during the period. 111 Capital’s holdings in Bristol Myers Squibb were worth $206,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. MCF Advisors LLC increased its stake in Bristol Myers Squibb by 112.4% during the 4th quarter. MCF Advisors LLC now owns 15,886 shares of the biopharmaceutical company’s stock worth $857,000 after buying an additional 8,406 shares in the last quarter. First Command Advisory Services Inc. increased its stake in Bristol Myers Squibb by 33.2% during the 4th quarter. First Command Advisory Services Inc. now owns 2,518 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 628 shares in the last quarter. OneAscent Financial Services LLC increased its stake in Bristol Myers Squibb by 29.2% during the 4th quarter. OneAscent Financial Services LLC now owns 12,575 shares of the biopharmaceutical company’s stock worth $678,000 after buying an additional 2,840 shares in the last quarter. Ipsen Advisor Group LLC increased its stake in Bristol Myers Squibb by 3.7% during the 4th quarter. Ipsen Advisor Group LLC now owns 11,160 shares of the biopharmaceutical company’s stock worth $602,000 after buying an additional 400 shares in the last quarter. Finally, Pinebridge Investments LLC purchased a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $37,013,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Guggenheim reiterated a “buy” rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Piper Sandler restated an “overweight” rating and issued a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Bank of America dropped their price target on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Finally, HSBC upped their price target on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research report on Tuesday, March 17th. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and an average target price of $61.31.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The European Commission approved Opdivo plus AVD as the first immunotherapy-based frontline regimen for previously untreated stage III or IV classical Hodgkin lymphoma in the EU, which could expand Bristol Myers Squibb’s reach in a key oncology market. How Investors May Respond To Bristol Myers Squibb (BMY) Winning EU Nod For First-Line Opdivo Regimen
• Positive Sentiment: At ASCO 2026, Bristol Myers Squibb highlighted promising late-stage cancer data, including Phase 3 results for mezigdomide in relapsed or refractory multiple myeloma and survival data for izalontamab brengitecan, reinforcing the company’s pipeline momentum. Bristol-Myers Squibb Cancer Wins Test Investor Patience On Valuation
• Positive Sentiment: Arcus Biosciences and Bristol Myers Squibb expanded their kidney cancer collaboration to advance casdatifan combinations in ccRCC, giving BMY another clinical-development opportunity in oncology. Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
• Neutral Sentiment: Several articles noted that Bristol Myers Squibb remains attractive to value and dividend-focused investors, with commentary pointing to its yield and dividend durability rather than a major near-term catalyst. Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock
• Neutral Sentiment: Bristol Myers Squibb also drew attention from an options-volume report, suggesting heightened trading interest, though the item did not point to a specific fundamental driver. Bristol Myers Squibb Sees Unusually High Options Volume (NYSE:BMY)

Bristol Myers Squibb Trading Down 0.1%

BMY opened at $57.24 on Monday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The stock has a market capitalization of $116.88 billion, a PE ratio of 16.08, a P/E/G ratio of 0.16 and a beta of 0.24. The business’s 50 day moving average price is $58.10 and its 200 day moving average price is $56.59. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same period in the prior year, the firm posted $1.80 earnings per share. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts expect that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.